Skip to main content
Premium Trial:

Request an Annual Quote

See, You Can Go from Industry to Academia

Marc Tessier-Lavigne, the executive vice president for research and the chief scientific officer at Genentech, is leaving the company to take the helm of Rockefeller University in New York, reports the New York Times. Tessier-Lavigne will take up the position in March, succeeding Paul Nurse, who is returning to the UK to lead the Royal Society there. The Times notes that Tessier-Lavigne is the "first departure from the company’s top scientific ranks since its acquisition by Roche in March 2009," but adds that Tessier-Lavigne's departure is not related to the Roche-Genentech merger. "I wasn't looking to move away. In fact, this is probably the only job that could have lured me away from Genentech," he says. Tessier-Lavigne will also be the first Rockefeller president to come from industry, the Times adds.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.